Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study

Background This study investigated the safety and efficacy of an anti–CTLA‐4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti–PD‐1 monoclonal antibody (CS1003) in patients with advanced/metastatic solid tumors. Methods The phase 1 study involved phase 1a monotherapy dose‐e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2024-06, Vol.130 (11), p.1991-2002
Hauptverfasser:	Bishnoi, Sarwan, Kotasek, Dusan, Aghmesheh, Morteza, Yau, Thomas, Cosman, Rasha, Prawira, Amy, Moore, Maggie, Chan, Stephen L., Mant, Andrew, Eek, Richard, Zielinski, Robert, Su, Rila, Pan, Zhaoxuan, Ma, Yiding, Li, Fei, Li, Peiqi, Tse, Archie N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Anticancer properties Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity anti‐programmed cell death protein 1 monoclonal antibody anti–CTLA‐4 monoclonal antibody Apoptosis Cell activation Cell death CS1002 CS1003 CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - immunology Dosage Dose-Response Relationship, Drug Effectiveness Female Hepatocellular carcinoma Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunoglobulin G Immunoglobulins Ligands Liver cancer Male Maximum Tolerated Dose Melanoma Metastases Microsatellite instability microsatellite instability‐high Microsatellites Middle Aged Mismatch repair mismatch repair‐deficient Monoclonal antibodies Neoplasms - drug therapy Neoplasms - pathology Programmed Cell Death 1 Receptor - antagonists & inhibitors Safety Safety management Solid tumors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!